Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease
Aline Floch, Alexandre Morel, Fabian Zanchetta-Balint, Catherine Cordonnier-Jourdin, Slimane Allali, Maximilien Grall, Ghislaine Ithier, Benjamin Carpentier, Sadaf Pakdaman, Jean‐Claude Merle, Radjiv Goulabchand, Tackwa Khalifeh, Ana Berceanu, Cécile Helmer, Christelle Chantalat‐Auger, Véronique Frémeaux-Bacchi, Marc Michel, Mariane de Montalembert, Armand Mekontso Dessap, France Pirenne, Anoosha Habibi, Pablo Bartolucci
Abstract
Continuous variables are expressed as means one standard deviation (SD) or medians (MD, [interquartile range]), depending on whether they are normally or asymmetrically distributed. Categorical variables are expressed as numbers (%). For comparison with the largest published delayed hemolytic transfusion reaction (DHTR) series, the data in column 2 are reprinted from Habibi et al.1 with permission. The patients of our series, who received anti-C5 antibody, had very severe DHTR with hyperhemolysis (P-values in column 3 compare our patients with those of the historical series). *Six patients had not even been discharged, due to the severity of their DHTR, **All patients in both series also received supportive vaso-occlusive crisis (VOC) treatment, hydration, oxygenation, and analgesia. Values were converted to g/L (from g/dL in Habibi et al.). Delta hemoglobin ( Hb) is the difference between the highest and lowest values available post-transfusion. F